GeneDx (WGS) to Release Earnings on Wednesday

GeneDx (NASDAQ:WGS) will likely be issuing its Q1 2025 quarterly earnings data before the market opens on Wednesday, April 30th. Analysts expect the company to announce earnings of $0.11 per share and revenue of $79.90 million for the quarter. GeneDx has set its FY 2025 guidance at EPS.

GeneDx (NASDAQ:WGS) last announced its quarterly earnings results on Tuesday, February 18th. The company reported $0.70 EPS for the quarter, beating analysts’ consensus estimates of $0.04 by $0.66. The business had revenue of $95.64 million for the quarter, compared to analyst estimates of $82.24 million. GeneDx had a negative net margin of 17.12% and a positive return on equity of 3.33%. On average, analysts expect GeneDx to post $1 EPS for the current fiscal year and $2 EPS for the next fiscal year.

GeneDx Stock Performance

WGS opened at $112.49 on Tuesday. The company has a debt-to-equity ratio of 0.25, a current ratio of 2.40 and a quick ratio of 2.27. The company has a market capitalization of $3.16 billion, a PE ratio of -57.39 and a beta of 1.93. The business has a fifty day simple moving average of $95.80 and a 200 day simple moving average of $82.37. GeneDx has a 1 year low of $10.70 and a 1 year high of $116.24.

Analysts Set New Price Targets

Several research firms recently commented on WGS. TD Cowen upped their price target on shares of GeneDx from $75.00 to $118.00 and gave the company a “buy” rating in a research note on Tuesday, January 7th. The Goldman Sachs Group raised their target price on shares of GeneDx from $70.00 to $80.00 and gave the stock a “neutral” rating in a report on Wednesday, February 19th. Three equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. According to MarketBeat, GeneDx presently has an average rating of “Moderate Buy” and an average target price of $72.33.

Insiders Place Their Bets

In other GeneDx news, CEO Katherine Stueland sold 46,594 shares of the company’s stock in a transaction on Wednesday, April 9th. The stock was sold at an average price of $89.62, for a total transaction of $4,175,754.28. Following the completion of the sale, the chief executive officer now directly owns 1,720 shares in the company, valued at $154,146.40. This represents a 96.44 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Kevin Feeley sold 402 shares of GeneDx stock in a transaction on Thursday, March 13th. The shares were sold at an average price of $90.05, for a total value of $36,200.10. Following the completion of the transaction, the chief financial officer now owns 5,044 shares in the company, valued at approximately $454,212.20. The trade was a 7.38 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 138,780 shares of company stock worth $12,907,437 over the last ninety days. Corporate insiders own 27.30% of the company’s stock.

About GeneDx

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.